Patent · US Active

Triazolo-pyrimidine compounds and uses thereof

US10858365B2 · kind B2 · utility

1Cited by

0References

9Claims

0Family size

Inventors

Qingbei Zeng · Shanghai, CN
Changhe Qi · Shanghai, CN
Honchung Tsui · Shanghai, CN
Zhenfan Yang · Shanghai, CN
Xiaolin Zhang · Singapore, SG

Key dates

Filing date	Jun 24, 2020
Grant date	Dec 8, 2020
Priority date	—
Expiry date	Jun 24, 2040

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K45/06
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to novel triazolo-pyrimidine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.